About the Author
My name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market. I have also worked extensively with an array of medical societies and patient organizations providing strategic communications counsel and media training.
Category Archives: Business/Industry News
Principles for COVID-19 Healthcare Communications – 1 Keep it Simple, Keep it Organized
On February 21 I published a piece on LinkedIn – Communications Considerations for Medical Manufacturers as the COVID-19 Epidemic Emerges – that provided an overview of some of the communications considerations for pharma, biotech and device manufacturers related to the … Continue reading
Posted in Business/Industry News, Crisis Communications, Current Affairs, Useful Resources
Comments Off on Principles for COVID-19 Healthcare Communications – 1 Keep it Simple, Keep it Organized
Morningstar on the Wyeth/Pfizer News
Posted in Business/Industry News
Comments Off on Morningstar on the Wyeth/Pfizer News
More on the Complete Response Letter Track Record and Stock Impact
Last week, I ran a chart on the track record of Complete Response Letters versus approvals from the FDA, demonstrating that the latter is losing in favor of the former. Since then, the balance of power has changed even further. … Continue reading
Posted in Approval Announcements, Business/Industry News
Comments Off on More on the Complete Response Letter Track Record and Stock Impact
Bristol-Myers Squibb to Commence Cash Tender Offer for ImClone Systems at $62.00 per share
NEW YORK, September 22, 2008 – Bristol-Myers Squibb Company (NYSE: BMY) today announced that it is increasing its initial offer for ImClone Systems Incorporated (NASDAQ: IMCL) and intends to commence a tender offer for the currently outstanding shares of common … Continue reading
Posted in Business/Industry News
Comments Off on Bristol-Myers Squibb to Commence Cash Tender Offer for ImClone Systems at $62.00 per share
Genentech Committee Responds to Roche Purchase Proposal
Genentech’s special committee formed to help the Board of Directors pose a response to the Roche purchase proposal has stated that they feel the offer "substantially undervalues" the company, but left open the door for a new bid. Here is … Continue reading
Posted in Business/Industry News
1 Comment